Last reviewed · How we verify
Standard TB treatment — Competitive Intelligence Brief
phase 3
Antimycobacterial combination therapy
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Standard TB treatment (Standard TB treatment) — The Aurum Institute NPC. Standard TB treatment uses a combination of antimicrobial agents that inhibit bacterial cell wall synthesis and protein synthesis to kill or suppress Mycobacterium tuberculosis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Standard TB treatment TARGET | Standard TB treatment | The Aurum Institute NPC | phase 3 | Antimycobacterial combination therapy |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antimycobacterial combination therapy class)
- The Aurum Institute NPC · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Standard TB treatment CI watch — RSS
- Standard TB treatment CI watch — Atom
- Standard TB treatment CI watch — JSON
- Standard TB treatment alone — RSS
- Whole Antimycobacterial combination therapy class — RSS
Cite this brief
Drug Landscape (2026). Standard TB treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-tb-treatment. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab